Clinical study of correlation between C-terminal cross-linking telopeptide of type I collagen and risk assessment, severity of disease, healing after early surgical intervention in patients with bisphophonate-related osteonecrosis of the jaws.
10.5125/jkaoms.2011.37.1.1
- Author:
Jin Woo SONG
1
;
Ki Hyun KIM
;
Jae Min SONG
;
Byung Do CHUN
;
Yong Deok KIM
;
Uk Kyu KIM
;
Sang Hun SHIN
Author Information
1. Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University, Yangsan, Korea. ssh8080@pusan.ac.kr
- Publication Type:Original Article
- Keywords:
Bisphosphonates;
Osteonecrosis;
Bisphosphonate-related osteonecrosis of the jaws (BRONJ);
Jaw diseases;
Collagen type I trimeric cross-linked peptide
- MeSH:
Alendronate;
Bisphosphonate-Associated Osteonecrosis of the Jaw;
Collagen Type I;
Diphosphonates;
Etidronic Acid;
Humans;
Imidazoles;
Jaw;
Jaw Diseases;
Osteonecrosis;
Peptides;
Risk Assessment;
Risedronate Sodium
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2011;37(1):1-8
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
INTRODUCTION: The utility of the C-terminal cross-linking telopeptide test (CTX) as a method for staging Bisphosphonate-related osteonecrosis of the jaws (BRONJ) and its healing process was examined. MATERIALS AND METHODS: A total 19 patients who were diagnosed with BRONJ underwent a fasted morning CTX test, were enrolled in this study. The serum CTX values ranged from 50 to 630 pg/mL (mean 60). The risk assessment was rated according to the CTX values of the individual patient (minimal risk, > or =150 pg/mL, moderate, 100 to 150 pg/mL, high, < or =100 pg/mL). The BRONJ scores were then calculated according to the number of BRONJ lesions and their stage. The operation was done as soon as possible, regardless of BORNJ stage. RESULTS: The mean duration of bisphosphonate therapy was 4.1 years. Of the 19 patients, 15, 2 ans 2 received alendronate, risedronate and zoledronate, respecively. Of the 19 patients who underwent a sequestrectomy, saucerization and smoothing, 15 healed after the initial surgery, 1 patient healed after one more surgical procedure, 3 patients did not heal completely but showed improvement in symptoms. Therefore, 17 out of the 19 patients healed completely with complete mucosal coverage and the elimination of pain. The risk assessment using the CTX value and disease severity were not correlated (r=-0.264, P=0.275). In addition, the risk assessment using CTX value and healing after surgery were not correlated (r=-0.147, P=0.547). CONCLUSION: The serum CTX should be considered carefully by clinicians as part of overall management. Early surgical intervention is of benefit in the treatment of stage II BRONJ.
